









Markets
/
Stocks
/
nasdaq-nuvb
/

Nuvation Bio Inc

NUVB

5.700USD

+0.080+1.42%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.95BMarket Cap

LossP/E TTM



Nuvation Bio Inc

5.700

+0.080+1.42%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nuvation Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Nuvation Bio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.40.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nuvation Bio Inc's Score

Industry at a Glance

Industry Ranking

105 / 392

Overall Ranking

235 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Nuvation Bio Inc Highlights

StrengthsRisks

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.87M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 7.87M.

Undervalued

The company’s latest PE is -11.45, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 226.59M shares, decreasing 14.00% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 353.69K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.61.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

11.400

Target Price

+102.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Nuvation Bio Inc is 6.93, ranking 183 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 13.12M, representing a year-over-year increase of 1704.68%, while its net profit experienced a year-over-year increase of 35.38%.

Score

Industry at a Glance

Previous score

6.93

Change



Financials

5.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Nuvation Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Nuvation Bio Inc is 6.08, ranking 333 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.45, which is -93.42% below the recent high of -0.75 and -67.37% above the recent low of -19.17.

Score

Industry at a Glance

Previous score

6.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Nuvation Bio Inc is 8.18, ranking 155 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 12.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.18

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

11.400

Target Price

+94.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Nuvation Bio Inc

NUVB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Nuvation Bio Inc is 7.01, ranking 120 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.78 and the support level at 4.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.96

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.104

Neutral

RSI(14)

38.437

Neutral

STOCH(KDJ)(9,3,3)

54.088

Neutral

ATR(14)

0.384

Low Volatility

CCI(14)

50.063

Neutral

Williams %R

48.673

Neutral

TRIX(12,20)

-1.592

Sell

StochRSI(14)

64.540

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

5.742

Sell

MA10

5.570

Buy

MA20

5.936

Sell

MA50

7.523

Sell

MA100

5.939

Sell

MA200

4.169

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Nuvation Bio Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 66.29%, representing a quarter-over-quarter decrease of 0.66%. The largest institutional shareholder is The Vanguard, holding a total of 15.50M shares, representing 4.53% of shares outstanding, with 0.56% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hung (David T)

60.28M

+0.84%

Fidelity Management & Research Company LLC

50.06M

-0.82%

Decheng Capital LLC

25.95M

BlackRock Institutional Trust Company, N.A.

19.98M

-4.84%

The Vanguard Group, Inc.

Star Investors

15.40M

-2.83%

Laurion Capital Management LP

9.71M

-5.23%

Omega Fund Management, LLC

8.83M

-20.03%

State Street Investment Management (US)

6.09M

+9.54%

Geode Capital Management, L.L.C.

5.89M

-1.79%

Millennium Management LLC

4.85M

-9.81%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nuvation Bio Inc is 3.85, ranking 117 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Nuvation Bio Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.